Covalent TLR7 NOD2 Agonist Conjugates for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack potent compounds that can simultaneously activate TLR7 and NOD2 receptors effectively, which are crucial for eliciting robust immune responses, particularly in vaccine adjuvants and therapeutic applications.
Innovation Solution
Development of novel covalent conjugates of TLR7 and NOD2 agonists, specifically designed compounds that are synthesized to activate both receptors, enhancing immune stimulation and potentially improving vaccine efficacy and therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate TLR7 agonist and NOD2 agonist are used, then each receptor can be activated, but the immunostimulatory activity is not sufficient and cannot elicit robust immune responses
Solution Approach 1:
The patent combines TLR7 agonist and NOD2 agonist into a single conjugate molecule, enabling simultaneous activation of both receptors. The conjugate structure links the imidazoquinoline TLR7 agonist portion with the NOD2 agonist portion through a linker, creating a dual-function molecule that elicits robust immune responses by engaging multiple pattern recognition receptors concurrently.
Solution Approach 2:
The conjugate molecule serves multiple functions: it acts as both a TLR7 agonist and a NOD2 agonist within a single compound. This multi-functional design allows the molecule to activate different immune pathways (endosomal TLR7 signaling and cytosolic NOD2 signaling) simultaneously, enhancing overall immunostimulatory activity and enabling broad-spectrum immune activation.
2Reliability
If covalent conjugate of TLR7 and NOD2 agonists is developed, then enhanced immunostimulatory activity and robust immune responses are achieved, but the compound structure and synthesis process become more complex
Solution Approach 1:
The conjugate is designed as a segmented molecule with distinct functional domains: a TLR7 agonist portion (imidazoquinoline core), a linker portion, and a NOD2 agonist portion. This segmentation allows each component to maintain its specific receptor-binding capability while being connected in a controlled manner, facilitating both robust immune activation and systematic synthesis through modular assembly of predefined building blocks.
Solution Approach 2:
The patent creates a composite molecular structure by covalently linking two different agonist molecules (TLR7 agonist and NOD2 agonist) through a chemical linker. This composite design integrates the functional properties of both parent molecules into a single hybrid compound, achieving synergistic immunostimulatory effects while maintaining a defined and characterizable molecular architecture.
3Reliability
If covalent conjugate of TLR7 and NOD2 agonists is developed, then enhanced immunostimulatory activity is achieved, but the synthesis process becomes more complex
Solution Approach 1:
The conjugate synthesis employs preliminary protection of reactive functional groups on the TLR7 agonist and NOD2 agonist components before coupling. This preliminary action prevents unwanted side reactions during the conjugation process and ensures high fidelity in forming the desired conjugate structure, thereby facilitating a more controlled and efficient synthesis process despite the molecular complexity.
Solution Approach 2:
The patent uses a chemical linker as an intermediary component to connect the TLR7 agonist and NOD2 agonist. This intermediary facilitates the conjugation reaction by providing reactive handles that can be coupled under mild conditions, and it can be designed to include protective groups or activation moieties that simplify the overall synthesis process while maintaining the integrity of both agonist portions.
Data Source
AI summary
This invention provides covalent conjugates of TLR7 and NOD2 agonists, processes for preparing such compounds and the use of such compounds in medicine.